Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Neurocrit Care. 2016 Aug;25(1):56–63. doi: 10.1007/s12028-015-0233-7

Table 1.

Patient characteristics

Simvastatin Placebo

N 13 12

Age 59 ± 12 60 ± 10

Gender – Female % 62% 67%

Race – Caucasian % 86% 92%

Smoker (%) 38% 50%

Hypertension (%) 23% 50%

Coronary artery disease (%) 0 8%

*HDL cholesterol (mean ± SD) 57 ± 18.3 63 ± 19.8

*LDL cholesterol (mean ± SD) 115 ± 51.9 81 ± 26.8

*Anti-platelet therapy (%) 0 8%

Heavy alcohol use (%) 7% 8%

Admitted on SAH day (%) Day of hemorrhage 10 Day of hemorrhage – 9
1 day post bleed - 3 1 day post bleed - 2
2 days post bleed - 1

* Mean blood pressure (mean ± SD) 107 ± 11.9 102 ± 23.2

Intubated (%) 7% 16%

*WFNS Grade(N) 2 – 4 2 – 2
3 – 6 3 – 3
4 – 1 4 – 5
5 – 2 5 – 2

*Modified Fisher Scale (N) 1 – 0 1 – 1
2 – 2 2 – 2
3 – 7 3 – 6
4 – 4 4 – 3

*Intraventricular hemorrhage(%) 46% 67%

Moderate/severe angiographic vasospasm (%) 42% 45%

Delayed cerebral ischemia with rescue therapy (%) 14% 55%

Modified Rankin Scale (6-month) N N
0 3 0
1 3 2
2 4 4
3 0 4
4 0 2
5 1 0
6 2 0
*

On admission